← Leaderboards
Michael G Dube
University Of Southern California
$1,076,796
Attributed
$1,076,796
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,076,796 · 6
By mechanism
M01$1,076,796 · 6
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Derick S Han$2,328,315
- Howard N Hodis$51,156,356
- Shu Chien$41,413,628
- Yves A Declerck$18,916,589
- Yingxiao Wang$19,926,530
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectAids TherapyHuman Therapy EvaluationClinical ResearchHiv InfectionsAntiaids AgentInsulin Sensitivity /ResistanceCarbohydrate MetabolismGlucose Tolerance TestIndinavirDrug Screening /EvaluationBody CompositionDrug Adverse EffectProtease InhibitorCombination ChemotherapyPharmacokineticsGlucoseAdipose TissueDrug Administration RoutesDisease /Disorder Proneness /RiskAidsCardiovascular DisorderImmunotherapyMetabolism
Grant awards (24)
INDINAVIR--EFFECT ON CARBOHYDRATE METABOLISM IN HIV PATIENTS$0
M01 · FY2002 · RR
SUBSTITUTING EFAVIRENZ FOR PROTEASE INHIBITOR IN HIV+ PTS AT RISK FOR CVD$0
M01 · FY2002 · RR
INDINAVIR--EFFECT ON CARBOHYDRATE METABOLISM IN HIV PTS$0
M01 · FY2002 · RR
ACTG 328--RHIL 2 BY IV OR SQ IN PATIENTS W/ HIV$0
M01 · FY2002 · RR
ACTG 328--RHIL 2 BY IV OR SQ IN PATIENTS W/ HIV$155,764
M01 · FY2001 · RR
SUBSTITUTING EFAVIRENZ FOR PROTEASE INHIBITOR IN HIV+ PTS AT RISK FOR CVD$155,764
M01 · FY2001 · RR
INDINAVIR--EFFECT ON CARBOHYDRATE METABOLISM IN HIV PTS$155,764
M01 · FY2001 · RR
INDINAVIR--EFFECT ON CARBOHYDRATE METABOLISM IN HIV PATIENTS$155,764
M01 · FY2001 · RR
INDINAVIR--EFFECT ON CARBOHYDRATE METABOLISM IN HIV PATIENTS$0
M01 · FY2001 · RR
ACTG 328--RHIL 2 BY IV OR SQ IN PATIENTS W/ HIV$0
M01 · FY2001 · RR
INDINAVIR--EFFECT ON CARBOHYDRATE METABOLISM IN HIV PTS$0
M01 · FY2001 · RR
SUBSTITUTING EFAVIRENZ FOR PROTEASE INHIBITOR IN HIV+ PTS AT RISK FOR CVD$0
M01 · FY2001 · RR
ACTG 328--RHIL 2 BY IV OR SQ IN PATIENTS W/ HIV$155,764
M01 · FY2000 · RR
INDINAVIR--EFFECT ON CARBOHYDRATE METABOLISM IN HIV PATIENTS$155,764
M01 · FY2000 · RR
INDINAVIR--EFFECT ON CARBOHYDRATE METABOLISM IN HIV PATIENTS$35,553
M01 · FY2000 · RR
INDINAVIR--EFFECT ON CARBOHYDRATE METABOLISM IN HIV PTS$35,553
M01 · FY2000 · RR
SUBSTITUTING EFAVIRENZ FOR PROTEASE INHIBITOR IN HIV+ PTS AT RISK FOR CVD$35,553
M01 · FY2000 · RR
ACTG 328--RHIL 2 BY IV OR SQ IN PATIENTS W/ HIV$35,553
M01 · FY2000 · RR
AMPRENAVIR AND CARBOHYDRATE /LIPID METABOLISM IN HIV PTS$0
M01 · FY2000 · RR
A5005S: GLUCOSE METABOLISM, LIPID DISORDERS, BODY COMPOSITION CHANGES$0
M01 · FY2000 · RR
SUBSTITUTING EFAVIRENZ FOR PROTEASE INHIBITOR IN HIV+ PTS AT RISK FOR CVD$0
M01 · FY2000 · RR
INDINAVIR--EFFECT ON CARBOHYDRATE METABOLISM IN HIV PTS$0
M01 · FY2000 · RR
A5005S: GLUCOSE METABOLISM, LIPID DISORDERS, BODY COMPOSITION CHANGES$0
M01 · FY2000 · RR
AMPRENAVIR AND CARBOHYDRATE /LIPID METABOLISM IN HIV PTS$0
M01 · FY2000 · RR